Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Dexamethasone Sodium Phosphate

FDA-approved product (ointment, ophthalmic), marketed as Decadron, Dexacen-4, Dexacort and 6 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Dexamethasone Sodium Phosphate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acne
  • Adrenal gland disease
  • Adrenal gland hyperfunction
  • Adrenocortical insufficiency
  • Allergic conjunctivitis
  • Allergic rhinitis
  • Ankylosing spondylitis
  • Aplastic anemia
  • Asthma
  • Atopic eczema
  • Autoimmune thrombocytopenic purpura
  • Brain edema
  • Bursitis
  • Cancer
  • Chorioretinitis
  • Choroiditis
  • and 66 more

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Corticosteroids for local oral treatment; Corticosteroids; Corticosteroids, moderately potent (group ii); Corticosteroids, moderately potent, other combinations; Corticosteroids, combinations for treatment of acne
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli36.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae32.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis31.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Dexamethasone Sodium Phosphate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Dexamethasone Sodium Phosphate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma

    NCT04762745 · start 2021-02

    Registered record
    Registry ID
    NCT04762745
    Conditions
    Relapsed, Refractory, Multiple Myeloma
    Interventions
    Pomalidomide; Bendamustine; Dexamethasone; Pomalidomide; Bendamustine; Dexamethasone; Pomalidomide; Bendamustine; Dexamethasone; Pomalidomide; Bendamustine; Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2021-02
    Completion
    2023-02
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapsed, Refractory, Multiple Myeloma
    InterventionPomalidomide; Bendamustine; Dexamethasone; Pomalidomide +8 more
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma

    NCT03641456 · start 2020-09-25

    Registered record
    Registry ID
    NCT03641456
    Conditions
    Myeloma; Newly Diagnosed; High Risk
    Interventions
    bortezomib; Lenalidomide; Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2020-09-25
    Completion
    2025-12-30
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyeloma; Newly Diagnosed; High Risk
    Interventionbortezomib; Lenalidomide; Dexamethasone
    PhasePhase 2
    Registry statusUnknown

  • Investigational Treatments for COVID-19 in Tertiary Care Hospital of Pakistan

    NCT04492501 · start 2020-04-01

    Registered record
    Registry ID
    NCT04492501
    Conditions
    Covid19; Cytokine Release Syndrome; Critical Illness; ARDS
    Interventions
    Therapeutic Plasma exchange; Convalescent Plasma; Tocilizumab; Remdesivir; Mesenchymal stem cell therapy
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2020-04-01
    Completion
    2020-07-20
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCovid19; Cytokine Release Syndrome; Critical Illness; ARDS
    InterventionTherapeutic Plasma exchange; Convalescent Plasma; Tocilizumab; Remdesivir +1 more
    PhaseNot applicable
    Registry statusCompleted

  • Episcleral Dexamethasone for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole

    NCT04120311 · start 2019-09-01

    Registered record
    Registry ID
    NCT04120311
    Conditions
    Macular Edema; Radiation Retinopathy; Branch Retinal Vein Occlusion; Epiretinal Membrane; Central Serous Retinopathy With Pit of Optic Disc; Commotio Retinae; Vitritis
    Interventions
    Episcleral Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2019-09-01
    Completion
    2024-09-30
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMacular Edema; Radiation Retinopathy; Branch Retinal Vein Occlusion; Epiretinal Membrane +3 more
    InterventionEpiscleral Dexamethasone
    PhasePhase 1
    Registry statusUnknown

  • Liposomal Bupivacaine Plus Bupivacaine Peripheral Nerve Blockade Versus Ropivacaine Plus Dexamethasone Peripheral Nerve Blockade for Arthroscopic Rotator Cuff Repair

    NCT04737980 · start 2019-07-18

    Registered record
    Registry ID
    NCT04737980
    Conditions
    Rotator Cuff Tears; Shoulder Pain
    Interventions
    Liposomal bupivacaine; Bupivacaine Hcl 0.5% Inj; Ropivacaine 0.5% Injectable Solution; Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2019-07-18
    Completion
    2020-03-18
    Enrolment
    92

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRotator Cuff Tears; Shoulder Pain
    InterventionLiposomal bupivacaine; Bupivacaine Hcl 0.5% Inj; Ropivacaine 0.5% Injectable Solution; Dexamethasone
    PhasePhase 4
    Registry statusCompleted

  • Differential Efficacy of Corticosteroid Solutions for Non-Operative Treatment of Digit Flexor Tenosynovitis

    NCT04002037 · start 2019-06-25

    Registered record
    Registry ID
    NCT04002037
    Conditions
    Trigger Finger
    Interventions
    Triamcinolone Acetonide 40mg/mL; Triamcinolone Acetonide 10mg/mL; Dexamethasone 4 mg/ml
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2019-06-25
    Completion
    2023-01-01
    Enrolment
    95

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTrigger Finger
    InterventionTriamcinolone Acetonide 40mg/mL; Triamcinolone Acetonide 10mg/mL; Dexamethasone 4 mg/ml
    PhasePhase 4
    Registry statusTerminated

  • Comparative Evaluation of the Effect of Prophylactic Intraligamentary Injection of Dexamethasone and Piroxicam on Postoperative Pain in Teeth With Symptomatic Irreversible Pulpitis

    NCT03745105 · start 2018-12-25

    Registered record
    Registry ID
    NCT03745105
    Conditions
    Postoperative Pain
    Interventions
    Dexamethasone sodium phosphate; Piroxicam Injectable Solution; Mepivacaine HCL
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2018-12-25
    Completion
    2019-12-01
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostoperative Pain
    InterventionDexamethasone sodium phosphate; Piroxicam Injectable Solution; Mepivacaine HCL
    PhaseNot applicable
    Registry statusUnknown

  • Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy

    NCT03532022 · start 2018-10-04

    Registered record
    Registry ID
    NCT03532022
    Conditions
    Congenital Adrenal Hyperplasia
    Interventions
    Chronocort®; Standard Care
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2018-10-04
    Completion
    2021-07-09
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCongenital Adrenal Hyperplasia
    InterventionChronocort®; Standard Care
    PhasePhase 3
    Registry statusWithdrawn

  • A Clinical Study to Assess the Efficacy and Safety of Dexamethasone Suspension for Cataract Surgery

    NCT03687931 · start 2018-08-26

    Registered record
    Registry ID
    NCT03687931
    Conditions
    Inflammation Eye
    Interventions
    Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2018-08-26
    Completion
    2019-02-28
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInflammation Eye
    InterventionDexamethasone
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma

    NCT02969837 · start 2017-07-10

    Registered record
    Registry ID
    NCT02969837
    Conditions
    Multiple Myeloma
    Interventions
    Elotuzumab; Carfilzomib; Lenalidomide; Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-07-10
    Completion
    2025-12-01
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma
    InterventionElotuzumab; Carfilzomib; Lenalidomide; Dexamethasone
    PhasePhase 2
    Registry statusCompleted

  • Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.

    NCT03158688 · start 2017-06-13

    Registered record
    Registry ID
    NCT03158688
    Conditions
    Relapsed Multiple Myeloma; Refractory Multiple Myeloma
    Interventions
    Dexamethasone; Daratumumab; Carfilzomib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-06-13
    Completion
    2022-04-15
    Enrolment
    466

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapsed Multiple Myeloma; Refractory Multiple Myeloma
    InterventionDexamethasone; Daratumumab; Carfilzomib
    PhasePhase 3
    Registry statusCompleted

  • Treatment of Primary CNS Lymphoma ( FTD )

    NCT05274139 · start 2017-03-02

    Registered record
    Registry ID
    NCT05274139
    Conditions
    Primary CNS Lymphoma (PCNSL)
    Interventions
    HD-MTX-Ara-C regimen; FTD regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-03-02
    Completion
    2019-03-02
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary CNS Lymphoma (PCNSL)
    InterventionHD-MTX-Ara-C regimen; FTD regimen
    PhasePhase 2
    Registry statusCompleted

  • The Comparative Study on the Efficacy and Safety of Single Acupoint and Matching Acupoints

    NCT03061396 · start 2017-02-17

    Registered record
    Registry ID
    NCT03061396
    Conditions
    Electro-acupuncture; Chemotherapy-induced Nausea and Vomiting
    Interventions
    Matching points PC6+CV12; Single points PC6
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2017-02-17
    Completion
    2018-05-28
    Enrolment
    208

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionElectro-acupuncture; Chemotherapy-induced Nausea and Vomiting
    InterventionMatching points PC6+CV12; Single points PC6
    PhaseNot applicable
    Registry statusUnknown

  • A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma

    NCT02903381 · start 2016-10-20

    Registered record
    Registry ID
    NCT02903381
    Conditions
    Smoldering Multiple Myeloma
    Interventions
    Nivolumab; Lenalidomide; Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-10-20
    Completion
    2021-09-16
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSmoldering Multiple Myeloma
    InterventionNivolumab; Lenalidomide; Dexamethasone
    PhasePhase 2
    Registry statusCompleted

  • Daratumumab in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma and Severe Renal Impairment

    NCT02977494 · start 2016-06

    Registered record
    Registry ID
    NCT02977494
    Conditions
    Multiple Myeloma
    Interventions
    Daratumumab; Bortezomib; Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-06
    Completion
    2021-06
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma
    InterventionDaratumumab; Bortezomib; Dexamethasone
    PhasePhase 2
    Registry statusCompleted